卒中高危人群血压干预策略及效果随机对照研究进展

doi:10.3969/j.issn.1006-7795.2026.01.003

首都医科大学学报 ›› 2026, Vol. 47 ›› Issue (1): 16-29.doi: 10.3969/j.issn.1006-7795.2026.01.003

卒中高危人群血压干预策略及效果随机对照研究进展

贾佳静^1,2，王春娟^1,2，姜勇 ^3,4，李子孝^1,2,5*

1.首都医科大学附属北京天坛医院神经系统疾病国家临床医学研究中心医疗质量研究部, 北京 100070；2.首都医科大学附属北京天坛医院国家神经系统疾病医疗质量控制中心办公室, 北京 100070；3.首都医科大学附属北京天坛医院中国神经系统疾病人群防治合作中心办公室, 北京 100070；4.首都医科大学附属北京天坛医院神经系统疾病国家临床医学研究中心大数据中心, 北京 100070；5.首都医科大学附属北京天坛医院神经病学中心血管神经病学科, 北京 100070

收稿日期:2025-12-03 修回日期:2025-12-05 出版日期:2026-02-21 发布日期:2026-02-02
通讯作者: 李子孝 E-mail:lizixiao2008@hotmail.com
基金资助:
四大慢病重大专项(2025ZD0546500)；北京市科学技术委员会,中关村科技园区管理委员会资助项目(Z251100006025003)。

Progress in randomized controlled trials on strategies and effects of blood pressure intervention in populations with higher risk of stroke

Jia Jiajing^1,2, Wang Chunjuan^1,2, Jiang Yong^3,4, Li Zixiao^1,2,5*

1.Department of Healthcare Quality Research, China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China;2.National Center for Healthcare Quality Management in Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China;3.National Collaborating Center for Neurological Disorders Prevention, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China; 4.Department of Big Data Center, National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China;5.Vascular Neurology, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China

Received:2025-12-03 Revised:2025-12-05 Online:2026-02-21 Published:2026-02-02
Supported by:
This study was supported by Noncommunicable Chronic Diseases-National Science and Technology Major Project(2025ZD0546500), Beijing Municipal Science & Technology Commission, Administrative Commission of Zhongguancun Science Park(Z251100006025003).

摘要/Abstract

摘要： 高血压是卒中最主要的可控危险因素之一，有效控制血压可显著降低卒中的发病率与死亡率，是卒中一级预防的核心环节。本文系统梳理了卒中高危人群血压干预相关随机对照研究的证据，聚焦强化降压、可穿戴设备与远程血压监测两大核心策略，深入剖析不同干预措施对血压控制及卒中风险的影响，旨在为基层医疗机构开展卒中高危人群一级预防工作提供循证依据与实践参考。

关键词: 随机对照研究, 高血压, 卒中, 高危人群, 血压干预, 血压监测

Abstract: Hypertension is one of the most prominent modifiable risk factors for stroke. Accurate blood pressure control can substantially reduce the incidence and mortality of stroke serves as the cornerstone of primary stroke prevention. This article systematically summarizes the evidence from randomized controlled trials relating to blood pressure interventions in populations with higher risk of stroke, with a focus on two core implementations: intensive blood pressure lowering and remote blood pressure monitoring with wearable devices. By conducting an in-depth analysis of the impacts of different intervention measures on blood pressure control and stroke risk, this article aims to provide evidence-based basis and practical references for primary medical institutions to carry out primary stroke prevention among populations with higher risks.

Key words: randomized controlled trial, hypertension, stroke, high-risk population, blood pressure intervention, blood pressure monitoring

中图分类号:

贾佳静, 王春娟, 姜勇, 李子孝. 卒中高危人群血压干预策略及效果随机对照研究进展[J]. 首都医科大学学报, 2026, 47(1): 16-29.

Jia Jiajing, Wang Chunjuan, Jiang Yong, Li Zixiao. Progress in randomized controlled trials on strategies and effects of blood pressure intervention in populations with higher risk of stroke[J]. Journal of Capital Medical University, 2026, 47(1): 16-29.

参考文献

［1］GBD 2023 Causes of Death Collaborators. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990－2023: a systematic analysis for the Global Burden of Disease Study 2023［J］. Lancet, 2025, 406(10513): 1811－1872.
［2］GBD 2023 Disease and Injury and Risk Factor Collaborators. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990－2023: a systematic analysis for the Global Burden of Disease Study 2023［J］. Lancet, 2025, 406(10513): 1873－1922.
［3］Ma Q F, Li R, Wang L J, et al. Temporal trend and attributable risk factors of stroke burden in China, 1990－2019: an analysis for the Global Burden of Disease Study 2019［J］. Lancet Public Health, 2021, 6(12): e897-e906.
［4］Tu W J, Zhao Z P, Yin P, et al. Estimated burden of stroke in China in 2020［J］. JAMA Netw Open, 2023, 6(3): e231455.
［5］Kitagawa K, Yamamoto Y, Arima H, et al. Effect of standard vs intensive blood pressure control on the risk of recurrent stroke: a randomized clinical trial and meta-analysis［J］. JAMA Neurol, 2019, 76(11): 1309－1318.
［6］Tan J, Gong E Y, Gallis J A et al. Primary care-based digital health-enabled stroke management intervention: long-term follow-up of a cluster randomized clinical trial［J］. JAMA Netw Open, 2024, 7(12): e2449561.
［7］Song J L, Wang X L, Wang B, et al. Learning implementation of a guideline based decision support system to improve hypertension treatment in primary care in China: pragmatic cluster randomised controlled trial［J］. BMJ, 2024, 386: e079143.
［8］Hansson L, Zanchetti A, Carruthers S G, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. ［J］. Lancet, 1998, 351(9118): 1755－1762.
［9］Sun Y X, Mu J J, Wang D W, et al. A village doctor-led multifaceted intervention for blood pressure control in rural China: an open, cluster randomised trial［J］. Lancet, 2022, 399(10339): 1964－1975.
［10］Guo X F, Sun G Z, Xu Y, et al. Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials［J］. Lancet, 2025, 406(10507): 1009－1019.
［11］SPRINT Research Group, Wright JT Jr, Williamson J D, et al. A randomized trial of intensive versus standard blood-pressure control［J］. N Engl J Med, 2015, 373(22): 2103－2116.
［12］Zhang W L, Zhang S Y, Deng Y, et al. Trial of intensive blood-pressure control in older patients with hypertension［J］. N Engl J Med, 2021, 385(14): 1268－1279.
［13］Sun G Z, Miao W, Liu S Y, et al. Intensive systolic blood pressure reduction and kidney and cardiovascular outcomes: a secondary analysis of a randomized clinical trial［J］. JAMA Netw Open, 2025, 8(7): e2519604.
［14］He J, Ouyang N X, Guo X F, et al. Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial［J］. Lancet, 2023, 401(10380): 928－938.
［15］Liu J M, Li Y, Ge J Z, et al. Lowering systolic blood pressure to less than 120 mmHg versus less than 140 mmHg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial［J］. Lancet, 2024, 404(10449): 245－255.
［16］Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels － updated overview and meta-analyses of randomized trials［J］. J Hypertens, 2016, 34(4): 613－622.
［17］Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis［J］. Lancet, 2021, 397(10285): 1625－1636.
［18］Blood Pressure Lowering Treatment Trialists' Collaboration. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis［J］. Lancet, 2021, 398(10305): 1053－1064.
［19］Guo X F, Ouyang N X, Sun G Z, et al. Multifaceted Intensive blood pressure control model in older and younger individuals with hypertension: a randomized clinical trial［J］. JAMA Cardiol, 2024, 9(9): 781－790.
［20］Sheppard J P, Burt J, Lown M, et al. Effect of antihypertensive medication reduction vs usual care on short-term blood pressure control in patients with hypertension aged 80 years and older: the OPTIMISE randomized clinical trial［J］. JAMA, 2020, 323(20): 2039－2051.
［21］Bi Y F, Li M, Liu Y, et al. Intensive blood-pressure control in patients with type 2 diabetes［J］. N Engl J Med, 2025, 392(12): 1155－1167.
［22］ACCORD Study Group, Cushman W C, Evans G W, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus［J］. N Engl J Med, 2010, 362(17): 1575－1585.
［23］Liu J. Highlights of the 2024 Chinese hypertension guidelines［J］. Hypertens Res, 2025, 48(3): 1048－1053.
［24］Schwalm J D, McCready T, Lopez-Jaramillo P, et al. A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial［J］. Lancet, 2019, 394(10205): 1231－1242.
［25］McManus R J, Mant J, Bray E P, et al. Telemonitoring and self-management in the control of hypertension(TASMINH2): a randomised controlled trial［J］. Lancet, 2010, 376(9736): 163－172.
［26］McManus R J, Mant J, Haque M S, et al. Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease: the TASMIN-SR randomized clinical trial［J］. JAMA, 2014, 312(8): 799－808.
［27］Fletcher B R, Hinton L, Hartmann-Boyce J, et al. Self-monitoring blood pressure in hypertension, patient and provider perspectives: a systematic review and thematic synthesis［J］. Patient Educ Couns, 2016, 99(2): 210－219.
［28］Mills K T, Obst K M, Shen W, et al. Comparative effectiveness of implementation strategies for blood pressure control in hypertensive patients: a systematic review and meta-analysis［J］. Ann Intern Med, 2018, 168(2): 110－120.
［29］Liyanage-Don N, Phillips E, Schwartz J E, et al. Implementing remote patient monitoring to improve hypertension control in a primary care network: rationale and design of the monitor-BP cluster randomized trial［J］. Am Heart J, 2025, 288: 52－64.
［30］Whelton P K, Carey R M, Aronow W S, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines［J］. Circulation, 2018, 138: e484-e594.
［31］McManus R J, Little P, Stuart B, et al. Home and online management and evaluation of blood pressure (HOME BP) using a digital intervention in poorly controlled hypertension: randomised controlled trial［J］. BMJ, 2021, 372: m4858.
［32］Zhang X Y, Wang S M, Zhou X Y, et al. A village doctor-led mobile health intervention for cardiovascular risk reduction in rural China: cluster randomised controlled trial［J］. BMJ, 2025, 389: e082765.
［33］Triantafyllidis A, Kondylakis H, Katehakis D, et al. Smartwatch interventions in healthcare: a systematic review of the literature［J］. Int J Med Inform, 2024, 190: 105560.
［34］McLean, G, Band R, Saunderson K, et al. Digital interventions to promote self-management in adults with hypertension systematic review and meta-analysis［J］. J Hypertens, 2016, 34(4): 600－612.
［35］Khoong E C, Olazo K, Rivadeneira N A, et al. Mobile health strategies for blood pressure self-management in urban populations with digital barriers: systematic review and meta-analyses［J］. NPJ Digit Med, 2021, 4(1): 114.
［36］Clifford N, Tunis R, Ariyo A, et al. Trends and gaps in digital precision hypertension management: scoping review［J］. J Med Internet Res, 2025, 27: e59841.
［37］Liu Y R, Qin Y S, Chen Q M, et al. Effectiveness of mobile health interventions on physical activity management in adults with hypertension: a systematic review and meta-analysis［J］. Int J Nurs Stud, 2025, 172: 105225.
［38］Gnanenthiran S R, Tan I, Atkins E R, et al. Transforming blood pressure control in primary care through a novel remote decision support strategy based on wearable blood pressure monitoring: the NEXTGEN-BP randomized trial protocol［J］. Am Heart J, 2023, 265: 50－58.
［39］Wei X L, Zhang Z T, Chong M K C, et al. Evaluation of a package of risk-based pharmaceutical and lifestyle interventions in patients with hypertension and/or diabetes in rural China: a pragmatic cluster randomised controlled trial［J］. PLoS Med, 2021, 18(7): e1003694.
［40］Milani R V, Lavie C J, Bober R M, et al. Improving hypertension control and patient engagement using digital tools［J］. Am J Med, 2017, 130(1): 14－20.
［41］Nomura A. Digital therapeutics in Japan: present and future directions［J］. J Cardiol, 2025, 85(5): 360－365.
［42］Kario K, Nomura A, Harada N, et al. A multicenter clinical trial to assess the efficacy of the digital therapeutics for essential hypertension: rationale and design of the HERB-DH1 trial［J］. J Clin Hypertens, 2020, 22(9): 1713－1722.
［43］Kim J Y, Wineinger N E, Steinhubl S R. The influence of wireless self-monitoring program on the relationship between patient activation and health behaviors, medication adherence, and blood pressure levels in hypertensive patients: a substudy of a randomized controlled trial［J］. J Med Internet Res, 2016, 18(6): e116.
［44］David C N, Iochpe C, Harzheim E, et al. Effect of mobile health interventions on lifestyle and anthropometric characteristics of uncontrolled hypertensive participants: secondary analyses of a randomized controlled trial［J］. Healthcare, 2023, 11(8): 1069.
［45］Zhang H B, Huo X Q, Ren L X, et al. Design and rationale of the comprehensive intelligent Hypertension managEment SyStem(CHESS)evaluation study: a cluster randomized controlled trial for hypertension management in primary care［J］. Am Heart J, 2024, 273: 90－101.
［46］Commodore-Mensah Y, Chen Y L, Ogungbe O, et al. Design and rationale of the cardiometabolic health program linked with community health workers and mobile health telemonitoring to reduce health disparities (LINKED-HEARTS) program［J］. Am Heart J, 2024, 275: 9－20.
［47］Nachman D, Gilan A, Goldstein N, et al. Twenty-four-hour ambulatory blood pressure measurement using a novel noninvasive, cuffless, wireless device［J］. Am J Hypertens, 2021, 34(11): 1171－1180.
［48］Kim J, Chang S A, Park S W. First-in-human study for evaluating the accuracy of smart ring based cuffless blood pressure measurement［J］. J Korean Med Sci, 2024, 39(2): e18.
［49］Parati G, Pengo M F, Avolio A, et al. Nocturnal blood pressure: pathophysiology, measurement and clinical implications. Position paper of the European Society of Hypertension［J］. J Hypertens, 2025, 43(8): 1296－1318.
［50］Li J, Jia H L, Zhou J K, et al. Thin, soft, wearable system for continuous wireless monitoring of artery blood pressure［J］. Nat Commun, 2023, 14(1): 5009.
［51］Kario K, Shimbo D, Tomitani N, et al. The first study comparing a wearable watch-type blood pressure monitor with a conventional ambulatory blood pressure monitor on in-office and out-of-office settings［J］. J Clin Hypertens, 2020, 22(2): 135－141.
［52］Anisha S A, Sen A, Ahmad B, et al. Exploring acceptance of digital health technologies for managing non-communicable diseases among older adults: a systematic scoping review［J］. J Med Syst, 2025, 49(1): 35.
［53］Rosenberg A, Untersteiner H, Guazzarini A G, et al. A digitally supported multimodal lifestyle program to promote brain health among older adults (the Lethe randomized controlled feasibility trial): study design, progress, and first results［J］. Alzheimers Res Ther, 2024, 16(1): 252.
［54］Wang Y G, Tan J H, Zhao J, et al. Wearable devices as tools for better hypertension management in elderly patients［J］. Med Sci Monit, 2025, 31: e946079.
［55］Tian M Y, Ajay V S, Dunzhu D, et al. A cluster-randomized, controlled trial of a simplified multifaceted management program for individuals at high cardiovascular risk (SimCard trial) in rural Tibet, China, and Haryana, India［J］. Circulation, 2015, 132(9): 815－824.
［56］Jafar T H, Gandhi M, De Silva H A, et al. A community-based intervention for managing hypertension in rural South Asia［J］. N Engl J Med, 2020, 382(8): 717－726.
［57］De Souza Ferreira E, De Oliveira A H M, Dias M A, et al. Mobile solution and chronic diseases: development and implementation of a mobile application and digital platform for collecting, analyzing data, monitoring and managing health care［J］. BMC Health Serv Res, 2024, 24(1): 1009.

[1]	田雪, 夏雪, 周全, 杨味滋, 郝允逸, 孙悦, 王安心, 张彤. 症状性颅内外动脉粥样硬化性狭窄卒中复发的危险因素分析与高危人群识别[J]. 首都医科大学学报, 2026, 47(1): 43-53.
[2]	张潇文, 唐涛, 李迪, 李深, 席春江. 急性前循环大血管闭塞性脑梗死进展速度的影响因素分析[J]. 首都医科大学学报, 2025, 46(4): 688-693.

卒中高危人群血压干预策略及效果随机对照研究进展

Progress in randomized controlled trials on strategies and effects of blood pressure intervention in populations with higher risk of stroke

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics

本文评价